Product Description
AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 from interacting with its ligands PD-L1 and PD-L2. (Sourced from: https://agenusbio.com/agen2034-anti-pd-1/)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Cervical CancerFast Track - Colorectal Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agenus
Company Location: LEXINGTON MA 02421
Company CEO: Garo H. Armen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Armenia, Australia, Belgium, Brazil, Chile, China, Estonia, France, Georgia, Hungary, Italy, Korea, Mexico, Moldova, Netherlands, Peru, Poland, Russia, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 28
Highest Development Phases
Phase 3: Adenocarcinoma|Colorectal Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified
Phase 2: Bladder Cancer|Brain Cancer|Cervical Cancer|Glioblastoma|Gliosarcoma|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Lymphoma|Melanoma|Non-Small-Cell Lung Cancer|Oropharyngeal Cancer|Pancreatic Cancer|Prostate Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Uterine Cancer
Phase 1: Endometrial Cancer|Hemangiosarcoma|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IMMONC0008 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-04-01 |
|
| IMMONC0001 | P2 |
Recruiting |
Lymphoma |
2029-09-01 |
|
| NEOASIS | P3 |
Recruiting |
Oncology Solid Tumor Unspecified |
2029-01-29 |
|
| BBOpCo | P2 |
Recruiting |
Colorectal Cancer |
2028-07-01 |